Erratum: Systemic Delivery of MicroRNA-101 Potently Inhibits Hepatocellular Carcinoma In Vivo by Repressing Multiple Targets (PLOS GENETICS (2015) 11:2 (e1004873) DOI: 10.1371/journal.pgen.1004873);Systemic Delivery of MicroRNA-101 Potently Inhibits Hepatocellular Carcinoma In Vivo by Repressing Multiple Targets

PLoS Genetics

Volumn 11, Issue 2, 2015, Pages 1-21

  Zheng, Fang ^a,b   Liao, Yi Ji ^a   Cai, Mu Yan ^a   Liu, Tian Hao ^a,b   Chen, Shu Peng ^a   Wu, Pei Hong ^a   Wu, Long ^c   Bian, Xiu Wu ^d   Guan, Xin Yuan ^a,e   Zeng, Yi Xin ^a   Yuan, Yun Fei ^a   Kung, Hsiang Fu ^a,f   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; LENTIVIRUS VECTOR; MICRORNA 101; RAC PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR EZH2; MICRORNA; MIRN101 MICRORNA, HUMAN; RHO KINASE; ROCK2 PROTEIN, HUMAN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; COX2 GENE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EZH2 GENE; FEMALE; GENE; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ROCK2 GENE; STMN1 GENE; TOXICITY TESTING; ANIMAL; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALIA; LENTIVIRUS; MUS;

ADULT; ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICRORNAS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84991922343     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1009960     Document Type: Erratum

References (47)

1. Roberts LR, (2008) Sorafenib in liver cancer—just the beginning. N Engl J Med 359: 420–422. doi: 10.1056/NEJMe0802241 18650519
2. Pisani P, Parkin DM, Bray F, Ferlay J, (1999) Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). Int J Cancer 83: 870–873. 10602059
3. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857–866. doi: 10.1038/nrc1997 17060945
4. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, et al. (2012) The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61: 278–289. doi: 10.1136/gut.2011.239145 21672940
5. Yang X, Zhang XF, Lu X, Jia HL, Liang L, et al. (2013) MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology 59(5):1874–85.
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834–838. doi: 10.1038/nature03702 15944708
7. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J, (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443–453. doi: 10.1038/nrd2310 17541417
8. Jimenez-Mateos EM, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, et al. (2012) Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med 18: 1087–1094. doi: 10.1038/nm.2834 22683779
9. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, et al. (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 105: 3903–3908. doi: 10.1073/pnas.0712321105 18308936
10. Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005–1017. doi: 10.1016/j.cell.2009.04.021 19524505
11. Su H, Yang JR, Xu T, Huang J, Xu L, et al. (2009) MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69: 1135–1142. doi: 10.1158/0008-5472.CAN-08-2886 19155302
12. Li S, Fu H, Wang Y, Tie Y, Xing R, et al. (2009) MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 49: 1194–1202. doi: 10.1002/hep.22757 19133651
13. Xu Y, An Y, Wang Y, Zhang C, Zhang H, et al. (2013) miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 29: 2019–2024. doi: 10.3892/or.2013.2338 23483142
14. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–7070. doi: 10.1158/0008-5472.CAN-05-1783 16103053
15. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, et al. (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5: 24. doi: 10.1186/1476-4598-5-24 16784538
16. Bottoni A, Zatelli MC, Ferracin M, Tagliati F, Piccin D, et al. (2007) Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol 210: 370–377. doi: 10.1002/jcp.20832 17111382
17. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, et al. (2009) MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 315: 1439–1447. doi: 10.1016/j.yexcr.2008.12.010 19133256
18. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, et al. (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695–1699. doi: 10.1126/science.1165395 19008416
19. Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, et al. (2013) c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology.
20. Hayashi Y, Tsujii M, Wang J, Kondo J, Akasaka T, et al. (2013) CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. Gut 62: 1536–1546. doi: 10.1136/gutjnl-2011-301625 22936674
21. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, et al. (2011) EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 60: 967–976. doi: 10.1136/gut.2010.231993 21330577
22. Wei X, Xiang T, Ren G, Tan C, Liu R, et al. (2013) miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 25: 439–446. doi: 10.1016/j.cellsig.2012.10.013 23124077
23. Weidner N, (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9–19. 7541613
24. Wang Y, Senoo H, Sesaki H, Iijima M, (2013) Rho GTPases orient directional sensing in chemotaxis. Proc Natl Acad Sci U S A 110: E4723–4732. doi: 10.1073/pnas.1312540110 24248334
25. Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, et al. (2014) Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer. Cell 156: 893–906. doi: 10.1016/j.cell.2013.12.043 24581491
26. Chiou GY, Chien CS, Wang ML, Chen MT, Yang YP, et al. (2013) Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. Mol Cell 52: 693–706. doi: 10.1016/j.molcel.2013.11.009 24332177
27. Bailey SN, Ali SM, Carpenter AE, Higgins CO, Sabatini DM, (2006) Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat Methods 3: 117–122. doi: 10.1038/nmeth848 16432521
28. Schambach A, Zychlinski D, Ehrnstroem B, Baum C, (2013) Biosafety features of lentiviral vectors. Hum Gene Ther 24: 132–142. doi: 10.1089/hum.2012.229 23311447
29. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, et al. (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467: 318–322. doi: 10.1038/nature09328 20844535
30. Flight MH, (2013) Trial watch: Clinical trial boost for lentiviral gene therapy. Nat Rev Drug Discov 12: 654. doi: 10.1038/nrd4111 23989781
31. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, et al. (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341: 1233151. doi: 10.1126/science.1233151 23845947
32. Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, et al. (2005) Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121: 425–436. doi: 10.1016/j.cell.2005.02.029 15882624
33. Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, et al. (2012) EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31: 583–594. doi: 10.1038/onc.2011.254 21685935
34. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, et al. (2011) FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell 43: 285–298. doi: 10.1016/j.molcel.2011.06.020 21777817
35. Tang TC, Poon RT, Lau CP, Xie D, Fan ST, (2005) Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 11: 1896–1902. 15800977
36. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T, (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38: 756–768. doi: 10.1053/jhep.2003.50380 12939602
37. Reichmann E, Schwarz H, Deiner EM, Leitner I, Eilers M, et al. (1992) Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 71: 1103–1116. doi: 10.1016/S0092-8674(05)80060-1 1473147
38. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, et al. (2006) Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549–558. doi: 10.1002/path.2011 16739096
39. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, et al. (2007) Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46: 200–208. doi: 10.1002/hep.21668 17596871
40. Wong CC, Wong CM, Tung EK, Man K, Ng IO, (2009) Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 49: 1583–1594. doi: 10.1002/hep.22836 19205033
41. He QW, Xia YP, Chen SC, Wang Y, Huang M, et al. (2013) Astrocyte-derived sonic hedgehog contributes to angiogenesis in brain microvascular endothelial cells via RhoA/ROCK pathway after oxygen-glucose deprivation. Mol Neurobiol 47: 976–987. doi: 10.1007/s12035-013-8396-8 23325464
42. Zhang Z, Yang M, Chen R, Su W, Li P, et al. (2013) IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways. Oncogene 33(26):3374–3382.
43. Chen L, Chan TH, Yuan YF, Hu L, Huang J, et al. (2010) CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest 120: 1178–1191. doi: 10.1172/JCI40665 20335658
44. Xu N, Bagumian G, Galiano M, Myat MM, (2011) Rho GTPase controls Drosophila salivary gland lumen size through regulation of the actin cytoskeleton and Moesin. Development 138: 5415–5427. doi: 10.1242/dev.069831 22071107
45. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513–10518. doi: 10.1073/pnas.0804549105 18663219
46. Huang Z, Huang D, Ni S, Peng Z, Sheng W, et al. (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118–126. doi: 10.1002/ijc.25007 19876917
47. Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, et al. (2012) Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut 61: 562–575. doi: 10.1136/gutjnl-2011-300207 21813470